A comprehensive narrative review published in Frontiers in Psychiatry has examined the potential of anesthetic and perioperative drugs to act as rapid-acting antidepressants, offering hope for patients with treatment-resistant depression (TRD) or those experiencing acute suicidal ideation. The review, led by researchers from the Department of Anesthesiology at the Second Affiliated Hospital of Jiaxing University in China, highlights that while conventional antidepressants can take weeks to work, certain anesthetic agents may improve depressive symptoms within hours to days.

According to the review, the most robust evidence exists for ketamine and its derivative esketamine. Ketamine, a racemic mixture of R- and S-enantiomers, and esketamine, the S-enantiomer, have been the subject of extensive clinical trials. The review notes that intravenous ketamine can rapidly reduce suicidal ideation, but it does not replace comprehensive suicide-prevention care. Intranasal esketamine has been shown to reduce depressive symptoms in adults with TRD and major depressive disorder (MDD) accompanied by acute suicidal ideation or behavior, though the review states that a separate effect on suicidal ideation or suicide prevention has not been demonstrated.

The review explains the proposed mechanism behind these rapid effects, which centers on synaptic plasticity. The authors describe a leading model where ketamine blocks N-methyl-D-aspartate (NMDA) receptors on GABAergic interneurons, leading to a brief disinhibition of pyramidal neurons and increased glutamate release. This shift toward α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor throughput triggers a cascade involving brain-derived neurotrophic factor (BDNF), tropomyosin receptor kinase B (TrkB), and mechanistic target of rapamycin complex 1 (mTORC1) signaling. This pathway, the review says, promotes rapid protein translation and structural remodeling, including the formation of new dendritic spines within hours in preclinical models.

However, the review cautions that this plasticity-centered cascade is largely derived from rodent studies. It states that it is uncertain whether these rapid molecular and structural changes observed in animals faithfully recapitulate processes in the human brain. Human neuroimaging studies have explored structural markers, but findings regarding volumetric changes in hippocampal subfields and their relationship with antidepressant efficacy remain inconsistent. The review notes that available human imaging results to date cannot directly corroborate the structural plasticity mechanisms documented in preclinical animal studies.

Beyond ketamine and esketamine, the review examines other agents. Nitrous oxide, also a noncompetitive NMDA-receptor antagonist, has encouraging phase 2 evidence. The review notes that the primary-outcome point estimate was modest with wide confidence intervals and narrowly missed conventional statistical significance. Propofol and volatile anesthetics remain experimental, with evidence limited to small studies. The review also discusses tramadol, an analgesic frequently used in perioperative practice, but states it is better viewed as a pharmacologic clue than as an antidepressant treatment.

The review emphasizes that clinical translation requires agent-specific monitoring, defined maintenance and stopping rules, and attention to cardiovascular, respiratory, cognitive, urinary, hepatic, and misuse risks. The authors searched PubMed, Embase, and Web of Science for publications up to 31 December 2025, and a supplementary check of publications from January to September 2026 identified no pivotal trials that would change their main conclusions.

For university students, this research is particularly relevant given the high prevalence of depression and suicidal ideation in this demographic. The potential for rapid-acting treatments could address a critical unmet need, but the review underscores that these drugs are not without risks and require careful medical supervision. The findings also highlight the importance of understanding the translational gap between preclinical research and clinical application, a key concept for students in neuroscience, psychology, and medical fields.